432 related articles for article (PubMed ID: 28913966)
21. Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms.
Burcu M; Dreyer NA; Franklin JM; Blum MD; Critchlow CW; Perfetto EM; Zhou W
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1228-1235. PubMed ID: 32162381
[TBL] [Abstract][Full Text] [Related]
22. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
[TBL] [Abstract][Full Text] [Related]
23. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
[TBL] [Abstract][Full Text] [Related]
24. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.
Berger ML; Dreyer N; Anderson F; Towse A; Sedrakyan A; Normand SL
Value Health; 2012; 15(2):217-30. PubMed ID: 22433752
[TBL] [Abstract][Full Text] [Related]
25. A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.
Berger ML; Martin BC; Husereau D; Worley K; Allen JD; Yang W; Quon NC; Mullins CD; Kahler KH; Crown W
Value Health; 2014 Mar; 17(2):143-56. PubMed ID: 24636373
[TBL] [Abstract][Full Text] [Related]
26. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
[TBL] [Abstract][Full Text] [Related]
27. Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making.
Solà-Morales O; Sigurðardóttir K; Akehurst R; Murphy LA; Mestre-Ferrandiz J; Cunningham D; de Pouvourville G
Value Health; 2023 Apr; 26(4S):32-42. PubMed ID: 36870678
[TBL] [Abstract][Full Text] [Related]
28. Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy.
Garrison LP; Neumann PJ; Willke RJ
J Manag Care Spec Pharm; 2019 Nov; 25(11):1185-1192. PubMed ID: 31663458
[TBL] [Abstract][Full Text] [Related]
29. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
Webster J; Smith BD
Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
[TBL] [Abstract][Full Text] [Related]
30. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
[TBL] [Abstract][Full Text] [Related]
31. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
32. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
[TBL] [Abstract][Full Text] [Related]
33. Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG).
Yuan H; Ali MS; Brouwer ES; Girman CJ; Guo JJ; Lund JL; Patorno E; Slaughter JL; Wen X; Bennett D;
Clin Pharmacol Ther; 2018 Aug; 104(2):239-241. PubMed ID: 29733448
[TBL] [Abstract][Full Text] [Related]
34. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
35. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
Neumann PJ; Willke RJ; Garrison LP
Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
[TBL] [Abstract][Full Text] [Related]
36. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.
Johnson ML; Crown W; Martin BC; Dormuth CR; Siebert U
Value Health; 2009; 12(8):1062-73. PubMed ID: 19793071
[TBL] [Abstract][Full Text] [Related]
37. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
38. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.
Jaime Caro J; Eddy DM; Kan H; Kaltz C; Patel B; Eldessouki R; Briggs AH;
Value Health; 2014 Mar; 17(2):174-82. PubMed ID: 24636375
[TBL] [Abstract][Full Text] [Related]
39. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.
Jansen JP; Trikalinos T; Cappelleri JC; Daw J; Andes S; Eldessouki R; Salanti G
Value Health; 2014 Mar; 17(2):157-73. PubMed ID: 24636374
[TBL] [Abstract][Full Text] [Related]
40. Selecting a dynamic simulation modeling method for health care delivery research-part 2: report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force.
Marshall DA; Burgos-Liz L; IJzerman MJ; Crown W; Padula WV; Wong PK; Pasupathy KS; Higashi MK; Osgood ND;
Value Health; 2015 Mar; 18(2):147-60. PubMed ID: 25773550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
